ALEPH-FARMS
30.8.2022 11:01:33 CEST | Business Wire | Press release
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that it has been officially recognized by the Agriculture Innovation Mission for Climate (AIM for Climate) as an Innovation Sprint Partner. As part of this innovation sprint, $40 million is being invested in cellular agriculture R&D over the next five years through Aleph Farms with the support of L Catterton, Strauss Group, VisVires New Protein, CPT Capital, Synthesis Capital, Food Tank and Christensen Global. Aleph Farms will introduce its products into global markets as soon as regulatory processes conclude and approvals are finalized.
The United States and the United Arab Emirates, alongside 39 other countries and over 180 non-governmental partners, officially launched the AIM for Climate initiative at the 26th United Nations Climate Change Conference of Parties (also known as COP26) in Glasgow, Scotland in 2021. The initiative galvanizes support and investments for innovation geared towards climate-smart agriculture and food systems, enabling solutions where global hunger and the climate crisis intersect. Of AIM for Climate’s four focal areas for innovation sprints in 2022, cellular agriculture addresses two in particular: methane reduction and emerging technologies in agriculture.
When supplementing sustainable segments of conventional animal agriculture, cellular agriculture can rapidly reduce emissions of methane, a powerful (yet short-lived) greenhouse gas of which livestock is a main source. Compared to conventional beef production, cultivated meat that is produced via cellular agriculture can reduce greenhouse gas emissions by 92% and water use by 78%, according to an independent Life Cycle Analysis conducted by CE Delft. Cultivated meat is also far more efficient than cows at converting feed into meat. By requiring 95% less land, cultivated meat opens up new opportunities for land use, including producing more food and re-wilding habitats for biodiversity, the latter of which further reduces emissions. In addition, because cultivated meat is produced in closed systems, its production is feasible in locations where extreme climate and resource scarcity prevent conventional beef production from taking place.
“Enhancing food security via cellular agriculture empowers communities and fosters regional cooperation, spurring economic growth in the process. This is why we are especially proud to be allocating these R&D funds as an AIM for Climate Innovation Sprint Partner,” said Didier Toubia, co-founder and CEO of Aleph Farms. “With cellular agriculture, humanity is better equipped to overcome significant food-related challenges and bring agricultural systems back into balance.”
Because meat represents only one-third of a cow slaughtered for conventional beef, Aleph Farms intends to continue expanding its product line to replace the whole cow. The company, the first to have grown steaks directly from non-genetically engineered animal cells, has also developed slaughter-free collagen, which has numerous applications across an array of multi-billion dollar industries.
About Aleph Farms
Aleph Farms grows cultivated beef steaks from cells that are isolated from a living cow and not immortalized or genetically modified, avoiding slaughter and achieving reduced environmental impact. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub by Strauss Group, and Professor Shulamit Levenberg of the Technion - Israel Institute of Technology. Its vision is to ensure unconditional nutrition for anyone, anytime, anywhere.
For its contributions to sustainability, Aleph Farms has received top accolades from the World Economic Forum, UNESCO, Netexplo Forum and EIT Food. The company is also part of the Private Sector Mechanism (PSM) at the UN Committee on World Food Security (CFS).
For more information, follow Aleph Farms on Instagram, Twitter, Facebook or LinkedIn or visit www.aleph-farms.com. Access the Aleph Farms press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI27.4.2026 10:00:00 CEST | Press release
Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operati
First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 08:00:00 CEST | Press release
First enterprise quantum computer purchase in Japan cements IQM's position as the global leader in deployed quantum computers The Radiance 20-qubit system will enable TOYO to explore various industry use cases, while advancing a hybrid quantum-HPC infrastructure. This will be the third quantum computer to be deployed by IQM in the Asia-Pacific region. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
